Lilly China deeply empowers local pharmaceutical research and development capabilities to leap, incubating innovation at the source with a global perspective
On August 31st, the "Gathering Ceremony, Creating Extraordinary - Lilly China Science Day" event was held at Zhangjiang Science City. On the spot, Lilly China officially announced that it had reached strategic cooperation with five local innovative biotechnology companies. This is another important manifestation of Lilly's commitment to continuously strengthening globalization and innovation in China, and achieving "rooted in China and benefiting China".
Lilly, which has successively established its China R&D center, regional headquarters, and China Innovation Cooperation Center in Pudong, is deeply empowering local pharmaceutical R&D capabilities through its own construction model, incubating innovation at the source with a global perspective, and further promoting the accelerated development of China's pharmaceutical industry.
Efficient combination of global experience and local innovation
Collaborative research and development accelerates China's innovative development
Biomedical industry is one of the three leading industries in Shanghai and also one of the six core industries that Pudong New Area focuses on developing. In the past 30 years, Pudong has developed into one of the regions with the most complete domestic biopharmaceutical industry chain, the best ecology, the most concentrated talents, the most active innovation, and the most fruitful achievements.
As a global leader in the healthcare industry, Eli Lilly is one of the first multinational pharmaceutical companies to carry out large-scale research and development activities in China, and also one of the earliest multinational pharmaceutical companies to establish partnerships with local Chinese enterprises in the field of new drug research and development.
Wu Qiang, Deputy District Mayor of Pudong New Area, attended the meeting and delivered a speech, stating that Lilly has successively laid out its China R&D center, regional headquarters, and China Innovation Cooperation Center in Pudong, playing a positive role in promoting the accelerated development of China's pharmaceutical industry, and also demonstrating the confidence of multinational pharmaceutical companies in Shanghai and their recognition of Pudong. "At present, Pudong is also actively promoting the development of the biopharmaceutical industry. We look forward to Lilly continuing to increase its layout in the Pudong New Area, supporting Pudong in building a 'science and technology innovation explosion point' with abundant innovation resources, a complete ecosystem, international influence, and a scale of billions of yuan. At the same time, we also hope to further promote scientific exchange and innovation cooperation through the 'Science Day' platform built by Lilly, and jointly build a comprehensive and open innovation ecosystem, contributing to the rapid development of China's pharmaceutical industry and the enhancement of international competitiveness."
In fact, over the past decade, Lilly China has established good research and development cooperation with multiple local enterprises by building independent research and development laboratories, promoting and managing collaborative research and development with external partners, and venture capital.
In 2018, Lilly China Innovation Cooperation Center was established in Zhangjiang, Pudong. Through its own mode of building the main body, Lilly is committed to effectively combining Lilly's global pharmaceutical experience with China's local innovative research and development, further promoting the accelerated development of China's pharmaceutical industry, effectively connecting China's current innovative ecological environment, better leveraging China's current favorable policy environment, faster promoting the development of new drugs, and bringing new breakthrough drugs to the world and Chinese patients.
At the meeting, it was revealed that after 5 years of development, the innovative products jointly developed by Lilly Innovation Cooperation Center and Chinese Biotechnology Company have had a huge impact on the lives of patients in China and globally. For example, the cooperation with Cinda Biology has laid the foundation for the research of PD-1 monoclonal antibody in China, and has cooperated with Junshi Biology to produce life saving neutralizing antibodies against COVID-19, which has become an important part of the combined therapy against COVID-19.
Dr. Ruth Gimeno, Vice President of Lilly diabetes, Obesity and Metabolic Diseases Research and Clinical Development Group, said: "The core team members of Lilly China Innovation Cooperation Center are all from Lilly Global Research and Development Center. They have many years of multinational pharmaceutical enterprises or overseas research background, and have rich experience in drug research and development and project management. As an important cooperation window of Lilly Global Research and Development in China, Lilly China Innovation Cooperation Center will continue to expand its pre clinical and early clinical research and development cooperation with China's outstanding biotechnology companies and academic institutions in various disease fields in the future, and is committed to achieving the common goal of 'China's innovation, serving the world'."
![Lilly China deeply empowers local pharmaceutical research and development capabilities to leap, incubating innovation at the source with a global perspective](https://a5qu.com/upload/images/2f9df9ef690c8288ec82c4a03e8e2609.jpg)
Zhangjiang Catalyst Incubation "From 0 to 1" Source Innovation
Multidimensional enabling local innovative pharmaceutical enterprise blueprint
In recent years, Lilly China Innovation Cooperation Center has been committed to innovative cooperation models and vigorously supports local biopharmaceutical startups. It has established strategic partnerships with over 20 local biopharmaceutical companies, including Xinda Biology, Junshi Biology, and Heyu Pharmaceutical.
In February 2022, the Zhangjiang catalytic converter was put into operation, and Eli Lilly continues to strengthen local pharmaceutical innovation cooperation. By adopting the method of self raised funds from Eli Lilly, we empower our partners and incubate "from 0 to 1" source innovation. Up to now, Lilly China Innovation Cooperation Center has provided technical and financial support and scientific consulting services for many Chinese local innovative enterprises, and provided exclusive research tools for cooperative enterprises by virtue of Lilly's rich global R&D experience, so as to achieve innovative cooperation modes such as technology empowerment, investment empowerment, and business empowerment, and help the development of local innovative drug enterprises in a multi-dimensional way.
"Eli Lilly has always been committed to supporting local biopharmaceutical innovation enterprises through internal research and development, cooperation with local pharmaceutical partners, and maximizing the efficient use of global resources to promote innovation project pipelines." Eli Lilly China President and General Manager Bei Liming said, "The implementation and promotion of various domestic policies have provided a favorable soil for the development of Chinese pharmaceutical innovation."
Text: Yang Zhenying, Qu Lichun
*Reprinted from official WeChat account released by Pudong